| Oral rivaroxaban for the treatment of symptomatic pulmonary embolism Einstein–PE Investigators New England journal of medicine 366 (14), 1287-1297, 2012 | 2965 | 2012 |
| Oral apixaban for the treatment of acute venous thromboembolism G Agnelli, HR Buller, A Cohen, M Curto, AS Gallus, M Johnson, ... New England Journal of Medicine 369 (9), 799-808, 2013 | 2908 | 2013 |
| Gemini: a family of highly capable multimodal models G Team, R Anil, S Borgeaud, JB Alayrac, J Yu, R Soricut, J Schalkwyk, ... arXiv preprint arXiv:2312.11805, 2023 | 2517 | 2023 |
| Venous thromboembolism (VTE) in Europe AT Cohen, G Agnelli, FA Anderson, JI Arcelus, D Bergqvist, JG Brecht, ... Thrombosis and haemostasis 98 (10), 756-764, 2007 | 2496 | 2007 |
| A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients MM Samama, AT Cohen, JY Darmon, L Desjardins, A Eldor, C Janbon, ... New England Journal of Medicine 341 (11), 793-800, 1999 | 2207 | 1999 |
| Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study AT Cohen, VF Tapson, JF Bergmann, SZ Goldhaber, AK Kakkar, ... The lancet 371 (9610), 387-394, 2008 | 2001 | 2008 |
| Apixaban for extended treatment of venous thromboembolism G Agnelli, HR Buller, A Cohen, M Curto, AS Gallus, M Johnson, A Porcari, ... New England Journal of Medicine 368 (8), 699-708, 2013 | 1748 | 2013 |
| Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer D Bergqvist, G Agnelli, AT Cohen, A Eldor, PE Nilsson, ... New England Journal of Medicine 346 (13), 975-980, 2002 | 1436 | 2002 |
| Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients A Leizorovicz, AT Cohen, AGG Turpie, CG Olsson, PT Vaitkus, ... Circulation 110 (7), 874-879, 2004 | 1260 | 2004 |
| Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial AT Cohen, BL Davidson, AS Gallus, MR Lassen, MH Prins, W Tomkowski, ... Bmj 332 (7537), 325-329, 2006 | 1094 | 2006 |
| Apixaban for the treatment of venous thromboembolism associated with cancer G Agnelli, C Becattini, G Meyer, A Muñoz, MV Huisman, JM Connors, ... New England Journal of Medicine 382 (17), 1599-1607, 2020 | 1040 | 2020 |
| Gemini 1.5: Unlocking multimodal understanding across millions of tokens of context G Team, P Georgiev, VI Lei, R Burnell, L Bai, A Gulati, G Tanzer, ... arXiv preprint arXiv:2403.05530, 2024 | 993 | 2024 |
| Andexanet alfa for acute major bleeding associated with factor Xa inhibitors SJ Connolly, TJ Milling Jr, JW Eikelboom, CM Gibson, JT Curnutte, A Gold, ... New England Journal of Medicine 375 (12), 1131-1141, 2016 | 985 | 2016 |
| Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors SJ Connolly, M Crowther, JW Eikelboom, CM Gibson, JT Curnutte, ... New England Journal of Medicine 380 (14), 1326-1335, 2019 | 983 | 2019 |
| Rivaroxaban or aspirin for extended treatment of venous thromboembolism JI Weitz, AWA Lensing, MH Prins, R Bauersachs, J Beyer-Westendorf, ... New England Journal of Medicine 376 (13), 1211-1222, 2017 | 873 | 2017 |
| Rivaroxaban for thromboprophylaxis in acutely ill medical patients AT Cohen, TE Spiro, HR Büller, L Haskell, D Hu, R Hull, A Mebazaa, ... New England Journal of Medicine 368 (6), 513-523, 2013 | 766 | 2013 |
| Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study R Alikhan, AT Cohen, S Combe, MM Samama, L Desjardins, A Eldor, ... Archives of internal medicine 164 (9), 963-968, 2004 | 736 | 2004 |
| Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies MH Prins, AWA Lensing, R Bauersachs, B Van Bellen, H Bounameaux, ... Thrombosis journal 11, 1-10, 2013 | 682 | 2013 |
| ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs antistreplase and of aspirin plus heparin vs aspirin along among 41 299 cases of suspected … D Hunt, J Varigos, F Dienstl, P Lechleitner, G De Backer, M Kornitzer, ... Lancet 339 (8796), 753-770, 1992 | 615 | 1992 |
| Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. JA Heit, AT Cohen, FA Anderson Jr Blood 106 (11), 910, 2005 | 547* | 2005 |
